Amphastar Pharmaceuticals Files 2024 10-K
Ticker: AMPH · Form: 10-K · Filed: 2025-03-03T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals, debt
TL;DR
AMPH 2024 10-K filed. Financials and debt details out.
AI Summary
Amphastar Pharmaceuticals, Inc. filed its 2024 10-K on March 3, 2025, reporting its fiscal year ending December 31, 2024. The filing details the company's financial performance and business operations. Key financial data points and disclosures regarding long-term debt and capital lease obligations are included, referencing FASB standards.
Why It Matters
This filing provides investors and analysts with a comprehensive overview of Amphastar's financial health and strategic positioning for the fiscal year 2024, influencing investment decisions.
Risk Assessment
Risk Level: medium — The filing is a standard annual report and does not inherently indicate new or elevated risks.
Key Numbers
- 2024 — Fiscal Year End (The period covered by the 10-K filing.)
- 2023 — Prior Fiscal Year End (For comparison with the current fiscal year's performance.)
- 2025-03-03 — Filing Date (The date Amphastar Pharmaceuticals, Inc. submitted this 10-K.)
Key Players & Entities
- Amphastar Pharmaceuticals, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-03 (date) — Filing date
- 11570 SIXTH STREET (address) — Company business and mail address
- RANCHO CUCAMONGA, CA 91730 (address) — Company business and mail city, state, zip
- 909-980-9484 (phone_number) — Company business phone
- 001-36509 (filing_number) — SEC file number
- 25698138 (film_number) — SEC film number
- Wells Fargo Bank (company) — Mentioned in relation to debt
- Two Thousand Twenty Nine (date) — Maturity year for convertible notes
FAQ
What were Amphastar Pharmaceuticals' total revenues for the fiscal year ending December 31, 2024?
The filing does not explicitly state the total revenues for the fiscal year ending December 31, 2024, within the provided header information. Detailed financial statements would be required to ascertain this figure.
What is the company's primary business address?
The company's business address is 11570 SIXTH STREET, RANCHO CUCAMONGA, CA 91730.
When are the Amphastar Pharmaceuticals' Two Percent Convertible Senior Notes due?
The Two Percent Convertible Senior Notes are due in Two Thousand Twenty Nine (2029).
What is the SEC file number for Amphastar Pharmaceuticals?
The SEC file number for Amphastar Pharmaceuticals is 001-36509.
Does the filing mention any specific debt instruments beyond convertible notes?
Yes, the filing references 'us-gaap:SecuredDebtMember' and 'amph:WellsFargoBankMember' in the context of debt as of December 31, 2024.
From the Filing
0001297184-25-000008.txt : 20250303 0001297184-25-000008.hdr.sgml : 20250303 20250303161615 ACCESSION NUMBER: 0001297184-25-000008 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 122 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250303 DATE AS OF CHANGE: 20250303 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Amphastar Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001297184 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330702205 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36509 FILM NUMBER: 25698138 BUSINESS ADDRESS: STREET 1: 11570 SIXTH STREET CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 BUSINESS PHONE: 909-980-9484 MAIL ADDRESS: STREET 1: 11570 SIXTH STREET CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 10-K 1 amph-20241231x10k.htm 10-K Amphastar Pharmaceuticals, Inc._December 31, 2024 http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligations P1Y 2021 2022 2023 2019 2020 2021 2022 2023 P3Y P5Y P3Y P5Y 0 0 0 0 Large Accelerated Filer 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 --12-31 false 0001297184 2024 FY P30D 0 0 false 2019 2020 2021 0 0 0 0 0 0 16400000 0001297184 amph:TwoPercentConvertibleSeniorNotesDueTwoThousandTwentyNineMember amph:WellsFargoBankMember 2023-01-01 2023-12-31 0001297184 us-gaap:SalesReturnsAndAllowancesMember 2024-01-01 2024-12-31 0001297184 us-gaap:SalesReturnsAndAllowancesMember 2023-01-01 2023-12-31 0001297184 us-gaap:SalesReturnsAndAllowancesMember 2024-12-31 0001297184 us-gaap:OtherNoncurrentLiabilitiesMember 2024-12-31 0001297184 us-gaap:SalesReturnsAndAllowancesMember 2023-12-31 0001297184 us-gaap:OtherNoncurrentLiabilitiesMember 2023-12-31 0001297184 us-gaap:SalesReturnsAndAllowancesMember 2022-12-31 0001297184 us-gaap:SecuredDebtMember amph:WellsFargoBankMember 2024-12-31 0001297184 amph:November2014ShareRepurchasePlanMember 2024-01-01 2024-12-31 0001297184 amph:November2014ShareRepurchasePlanMember 2023-01-01 2023-12-31 0001297184 amph:November2014ShareRepurchasePlanMember 2022-01-01 2022-12-31 0001297184 us-gaap:CaliforniaFranchiseTaxBoardMember us-gaap:ResearchMember 2024-12-31 0001297184 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-12-31 0001297184 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0001297184 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0001297184 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001297184 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001297184 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001297184 us-gaap:TreasuryStockCommonMember 2024-12-31 0001297184 us-gaap:RetainedEarningsMember 2024-12-31 0001297184 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001297184 us-gaap:TreasuryStockCommonMember 2023-12-31 0001297184 us-gaap:RetainedEarningsMember 2023-12-31 0001297184 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001297184 us-gaap:TreasuryStockCommonMember 2022-12-31 0001297184 us-gaap:RetainedEarningsMember 2022-12-31 0001297184 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001297184 us-gaap:TreasuryStockCommonMember 2021-12-31 0001297184 us-gaap:RetainedEarningsMember 2021-12-31 0001297184 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001297184 srt:MinimumMember amph:EquityPlan2015PlanAnd2005PlanMember 2024-01-01 2024-12-31 0001297184 srt:MaximumMember amph:EquityPlan2015PlanAnd2005PlanMember 2024-01-01 2024-12-31 0001297184 amph:The2015EquityIncentivePlanMember 2024-12-31 0001297184 amph:EmployeeStockPurchasePlan2014Member 2024-12-31 0001297184 amph:The2015EquityIncentivePlanMember 2015-03-18 0001297184 amph:EmployeeSt